Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

Mohammed Alnims

Status: Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Treatments: Drug: LCZ 696

Study type: Observational

Funder types: Other

Identifiers

NCT03816306

31640

Details and patient eligibility

About

To evaluate the clinical and echocardiographic outcome of LCZ696 therapy in HFrEF (NYHA Class II - IV and EF =≤ 40%).patients, in addition to the efficacy of LCZ696 in reducing mortality and rehospitalisation rate.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. ≥18 year old.
2. Functional class using New York Heart Association (NYHA) classification class II, III or IV %).
3. Left ventricular systolic dysfunction using transthoracic echocardiography with EF ≤ 40%.
4. Who was already taking ACE inhibitors or ARBs.

Exclusion criteria

1. Symptomatic hypotension.
2. Systolic blood pressure <100 mm Hg.
3. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2.
4. History of angioedema.
5. Hisotry of unacceptable side effects while on while on treatment with an ACE-inhibitor or ARBs.

Trial design

100 participants in 1 patient group

Single group study

Treatment:

Drug: LCZ 696